|
|
 |
|
|
|
|
International Symposium on Paget’s Disease
12-13 July 2007
St Catherine’s College, Manor Road, Oxford,
UK
PROGRAMME
|
|
Thursday
12 July |
| Joint Sessions |
| Advances in the Molecular
Pharmacology and Therapeutics of Bone Disease |
| and International Symposium
on Paget’s Disease |
|
|
08:30 |
Welcome and introduction |
|
Chairs: Graham Russell (Oxford,
UK) & Cyrus Cooper (Southampton, UK) |
|
|
08:40 |
Evolution of treatments for Paget’s Disease
and osteoporosis |
|
Paul Miller (Lakewood, USA) |
|
|
Bisphosphonate actions |
Chairs: Hal Ebetino
(Cincinnati, USA) & Greg
Mundy (Nashville, USA) |
|
|
09:10 |
The molecular mechanism of bisphosphonates |
|
Mike
Rogers (Aberdeen, UK) |
|
|
09:35 |
Alternate pathways of action of bisphosphonates
on bone cells |
|
Teresita
Bellido (Little Rock, USA) |
|
|
10:00 |
The biology of gamma-delta T cells and opportunities
for pharmacological intervention |
|
Andrew
Sewell (Cardiff) |
|
|
10:25 |
Coffee |
|
|
Therapeutic opportunities of
bisphosphonates in osteoporosis and other disorders |
Chairs: Peter Selby
(Manchester, UK) & Ian
Reid (Auckland, New Zealand) |
|
|
10:50 |
Effect of zoledronic acid 5 mg IV once yearly
on hip, spine, and non-spine fractures in patients with postmenopausal
osteoporosis |
|
Richard
Eastell (Sheffield, UK) |
|
|
11:20 |
Hip fracture: What are the reasons and opportunities
for pharmacologic intervention? |
|
Kenneth
Lyles (Durham, USA) |
|
|
11:50 |
Potential roles of bisphosphonates in
orthopaedic applications: aid in fracture healing, osteonecrosis
and implant fixation |
|
David
Little (Sydney, Australia) |
|
|
12:20 |
Potential roles of bisphosphonates in osteoarthritis |
|
Roy
Altman (Miami, USA) |
|
|
12:50 |
Lunch |
|
|
Current controversies in bisphosphonate
therapy |
Chairs: Eugene McCloskey
(Sheffield, UK) & Paul Miller
(Lakewood, USA) |
|
|
14:00 |
Bisphosphonates and oversuppression of bone
turnover: weighing the evidence |
|
Socrates
Papapoulos (Leiden, Netherlands) |
|
|
14:30 |
Sequential treatment of bisphosphonates and
PTH: challenging current assumptions |
|
Jürg
Gasser (Basel, Switzerland) |
|
|
15:00 |
Osteonecrosis of the jaw and bisphosphonates:
an update |
|
Erik
Eriksen (Basel, Switzerland) |
|
15:30 |
Tea |
|
|
16:00 |
Oral communications |
Chairs: Erik
Eriksen (Basle,Switzerland) & David
Little (Sydney,Australia) |
|
|
16:00
P1 |
CIRCULATING CATHEPSIN K LEVELS BEFORE AND
AFTER INTRAVENOUS BISPHOSPHONATE TREATMENT IN PAGET'S DISEASE
OF BONE |
|
V De Paola, L Gennari, D Merlotti, G Martini,
F Valleggi, A Avanzati, MB Franci, MS Campagna, R Nuti |
|
|
16:05
P2 |
EFFICACY AND SAFETY OF ZOLEDRONIC ACID IN
PAGETS DISEASE OF BONE: 4 YEARS OF EXPERIENCE
|
|
A Conesa Mateos, D Rotés Sala, L Pérez
Edo, J Carbonell Abelló
Department of Rheumatology. Hospital del Mar y Esperanza.
Instituto Municipal de Asistencia Sanitaria (I.M.A.S). Universidad
Autónoma. Barcelona, Spain |
|
|
16:10
P3 |
IS PLAIN ABDOMINAL X-RAY A SENSITIVE TOOL
FOR THE SCREENING OF PAGET DISEASE OF BONE? |
|
L. Corral-Gudino, J. García-Aparicio,
S. Gómez-Castro, C.A. Montilla, J del Pino-Montes
Servicio de Reumatología. Hospital Universitario de
Salmanca, Spain |
|
|
16:15
P4 |
LONG-TERM EFFECTS OF SINGLE ZOLEDRONATE OR
NERIDRONATE INFUSION IN PAGET'S DISEASE OF BONE |
|
D Merlotti, L Gennari, F Valleggi, V De Paola,
G Martini, A Avanzati, R Nuti
Department of Internal Medicine, Endocrine-Metabolic Sciences
and Biochemistry, University of Siena, Italy |
|
|
16:20
P5 |
MANAGEMENT OF PAGET'S DISEASE OF BONE: AN
AUDIT OF CLINICAL PRACTICE IN AUSTRALIA |
|
J P Walsh[1], R Attewell[2],
M J Hooper[3], J D Wark[4], S Fletcher[5],
V Ferrari[5], J A Eisman[6]
[1]Department of Endocrinology and Diabetes, Sir
Charles Gairdner Hospital, Nedlands, WA, Australia; [2]
Covance Pty Ltd, Braddon, ACT, Australia; [3] Bone
Research Program, ANZAC Research Institute, Concord Repatriation
Hospital, The University of Sydney and Central Sydney Area
Health Service, Sydney, NSW, Australia; [4] Department
of Medicine, University of Melbourne, Royal Melbourne Hospital,
Parkville, Victoria, Australia; [5] Novartis Pharmaceuticals
Australia Pty Ltd, North Ryde, NSW, Australia; [6]
Bone and Mineral Research Program, Garvan Institute of Medical
Research, Sydney, NSW, Australia. |
|
|
16:25
P6 |
RAPID PAIN RELIEF AND CLINICAL IMPROVEMENT
WITH INTRAVENOUS ZOLEDRONIC ACID IN LOCALIZED TRANSIENT OSTEOPOROSIS
OF THE HIP |
|
Ringe JD, Dorst A, Farahmand P. Medizin. Klinik
4 (Rheumatology, Osteology)Klinikum Leverkusen, University
of Cologne,Germany |
|
|
16:30
P7 |
TREATMENT OF HUNGARIAN PATIENTS WITH PAGET'S
DISEASE OF BONE WITH ZOLEDRONIC ACID |
|
J Donath, Zs Nagy, P Gergely Jr, Gy Poor
National Institute of Rheumatology and Physiotherapy, Budapest,
Hungary |
|
|
16:35 |
Close |
|
|
19:00 |
Dinner |
|
|
Friday 13
July |
International Symposium on
Paget’s Disease |
|
Epidemiology and genetics |
Chairs: Matt Brown
(Brisbane, Australia) & Luigi Gennari
(Siena, Italy) |
|
|
08:45 |
Update on epidemiology and pathogenesis of
Paget’s Disease |
|
Tim
Cundy (Auckland, New Zealand) |
|
|
09:15 |
Genetic basis of Paget’s Disease |
|
Stuart
Ralston (Edinburgh, UK) |
|
|
09:45 |
Valosin containing protein (VCP) mutations
in Paget's Disease, inclusion body myopathy and dementia,
and related disorders (tbc) |
| |
Virginia
Kimonis (Orange, USA) |
|
|
10:15 |
Coffee |
|
|
| Epidemiology and genetics
continued |
Chairs: Miep Helfrich
(Aberdeen, UK) & Stuart
Ralston (Edinburgh, UK) |
|
|
10:45 |
Genetic disorders of bone turnover, including
‘juvenile’ Paget’s Disease, and their management |
|
Michael
Whyte (St Louis, USA) |
|
|
|
11:15 |
Oral communications |
|
11:15
P8 |
A NOVEL MUTATION (P364S) UPSTREAM OF THE
UBA DOMAIN IN SEQUESTOSOME 1/P62 ASSOCIATED WITH PAGET'S DISEASE
WITH A MILD PHENOTYPE |
|
J P Walsh[1,2], A L Magno[1,2,3],
B K Ward[1,2,3], SL Rea[1,2,3], L Ward[1],
J Xu[1,2,3]
[1]Department of Endocrinology & Diabetes,
Sir Charles Gairdner Hospital, Nedlands, Australia; [2]School
of Medicine & Pharmacology, University of Western Australia,
Nedlands, Australia; [3]Western Australian Institute
for Medical Research, Nedlands, Australia |
|
|
11:20
P9 |
DISEASE-ASSOCIATED MUTATIONS IN THE SIGNAL
PEPTIDE OF RANK ALTER RANK LOCALISATION AND DOWNSTREAM ACTIVATION
OF NFKB. |
|
J. C. Crockett[1], M. Helfrich[1],
J.Greenhorn[1], D.I. Scott[1], A. Duthie[1],
S. H. Ralston[2], M. J. Rogers[1]
[1]Bone Research Group, University of Aberdeen,
Aberdeen, United Kingdom; [2]Molecular Medicine
Centre, University of Edinburgh, Edinburgh, United Kingdom |
|
|
11:25
P10 |
EFFECT OF SQSTM1 MUTATIONS ON BONE CELLS
IN VITRO |
|
L J Hocking, M J Rogers
University of Aberdeen, Aberdeen, UK |
|
|
11:30
P11 |
EFFECTS OF PAGET’S DISEASE OF BONE
MUTATIONS ON THE UBIQUITIN-BINDING FUNCTION OF SQSTM1 |
|
D Najat[1], L Bradley[1],
K Brownless[1], S Martin[1], A Falchetti[2],
F Marini[2], M L Brandi[2], B Shaw[1],
J R Cavey[1], R Layfield[1]
[1]University of Nottingham, UK; [2]University
of Florence, Italy |
|
|
11:35
P12 |
EVIDENCE OF ELEVATED ALP LEVELS IN CLINICALLY
UNAFFECTED RELATIVES OF SUBJECTS WITH FAMILIAL PAGET'S DISEASE
OF BONE |
|
L Gennari, D Merlotti, V De Paola, F Valleggi,
G Martini, A Avanzati, R Nuti
Department of Internal Medicine, Endocrine-Metabolic Sciences
and Biochemistry, University of Siena, Italy |
|
|
11:40
P13 |
IDENTIFICATION OF GENDER-SPECIFIC ASSOCIATION
BETWEEN TNFRSF11B POLYMORPHISMS AND PAGET'S DISEASE OF BONE |
|
G Beyens[1], A Daroszewska[2],
F de Freitas[1], E Fransen[1], F Vanhoenacker[3],
L Verbruggen[4], H Zmierczak[5], R Westhovens[6],
J Van Offel[7], S H Ralston[2], J P
Devogelaer[8], W Van Hul[1]
[1]Department of Medical Genetics, University and
University Hospital of Antwerp, Belgium; [2]Molecular
Medicine Centre, Western General Hospital, University of Edinburgh,
United Kingdom; [3]Department of Radiology, University
Hospital of Antwerp, Belgium; [4]Department of
Rheumatology, University Hospital of Brussels, Belgium; [5]Unit
of Osteoporosis and Metabolic Bone Diseases, University Hospital
of Ghent, Belgium; [6]Department of Rheumatology,
Catholic University of Leuven, Belgium; [7]Department
of Immunology and Rheumatology, University Hospital of Antwerp,
Belgium; [8]Department of Rheumatology, Saint-Luc
University Hospital, Université Catholique de Louvain,
Brussels, Belgium |
|
|
11:45
P14 |
MICE WITH A TRUNCATION MUTATION AFFECTING
SQSTM1 EXHIBIT SEVERAL PHENOTYPIC FEATURES IN COMMON WITH
PAGET'S DISEASE OF BONE. |
|
Javier Rojas[1], Anna Daroszewska[1],
Miep Helfrich[2], Rob Layfield[3], Rob
van 't Hof[1], Stuart Ralston[1]
[1]Molecular Medicine Centre, University of Edinburgh,
Western General Hospital, Edinburgh, UK; [2]Medicine
& Therapeutics, University of Aberdeen; [3]Institute
of Neuroscience, University of Nottingham |
|
|
11:50
P15 |
MUTATION AND HAPLOTYPE ANALYSIS OF THE SQSTM1
GENE IN BELGIAN PAGET'S DISEASE OF BONE PATIENTS |
|
P Y J Chung[1], G Beyens[1],
S Boonen[2], F E Offeciers[3], J Van
Offel[4], R Westhovens[5], H Zmierczak[6],
J P Devogelaer[7], W Van Hul[1]
[1]Department of Medical Genetics, University and
University Hospital of Antwerp, Belgium; [2]Center
for Metabolic Bone Diseases, University of Leuven, Belgium;
[3]Univ. ENT Dept, AZ St Augustinus, Wilrijk, University
of Antwerp, Belgium; [4]Department of Immunology
and Rheumatology, University Hospital of Antwerp, Belgium;
[5]Department of Rheumatology, Catholic University
of Leuven, Belgium; [6]Unit of Osteoporosis and
Metabolic Bone Diseases, University Hospital of Ghent, Belgium;
[7]Department of Rheumatology, Saint-Luc University
Hospital, Université Catholique de Louvain, Belgium |
|
|
11:55
P16 |
PREVALENCE OF SQSTM1 MUTATIONS IN SALAMANCA,
SPAIN |
|
E. Corral[1], L. Corral-Gudino[2],
J. García-aparicio[2], C.a. Montilla[2],
S. Gómez-Castro[2],J del Pino Montes[2],
R. González-Sarmiento[1]
[1]Unidad de Medicina Molecular. Universidad de
Salamanca; [2]Servicio de Reumaotología,
Hospital Universitario de Salamanca, Spain
|
|
|
12:00
P17 |
SQSTM1 MUTATIONS AND PAGET'S DISEASE OF BONE
– FUNCTIONAL AND STRUCTURAL STUDIES |
|
R Layfield[1], J Long[1],
J R Cavey[1], S Ralston[2], P W Sheppard[3],
M S Searle[1]. [1]University of Nottingham,
UK; [2]University of Edinburgh, UK; [3]BIOMOL
International LP, Exeter, UK |
|
|
12:05 |
Break |
|
|
|
|
Clinical studies |
Chairs: Bill Fraser
(Liverpool, UK) & Peter Selby (Manchester,
UK) |
|
|
12:15 |
What have we learned from the PRISM Study? |
|
Anne
Langston (Edinburgh, UK) |
|
|
12:45 |
Lunch and posters |
|
|
Experimental studies |
Chairs: Nick Athanasou
(Oxford, UK) & Tim
Cundy (Auckland, New Zealand) |
|
|
14:00 |
Experimental studies in Paget’s Disease |
|
David
Roodman (Pittsburgh, USA) |
|
|
14:30 |
Cellular biology in Paget’s Disease |
|
Ian
Reid (Auckland, New Zealand) |
|
|
15:00 |
Oral communications – Experimental
Studies |
Chairs: Jill Cornish
(Auckland, New Zealand) & Roger Smith
(Oxford, UK) |
|
|
15:00
P18 |
CANONICAL AND NON-CANONICAL MECHANISMS OF
OSTEOCLAST FORMATION IN PAGET'S DISEASE OF BONE |
|
F Jones, R Taylor, H Knowles, J Wass, NA Athanasou
Department of Pathology, Nuffield Orthopaedic Centre, Nuffield
Department of Orthopaedic Surgery, University of Oxford, OX3
7LD |
|
|
15:05
P19 |
P62 SIGNALING IN OSTEOCLASTS AND SURVIVAL
PATHWAYS |
|
E Chamoux[1], J Couture[1],
J P Brown[2], S Roux[1]
Department of Rheumatology, [1]Sherbrooke University,
Sherbrooke, [2]Laval University, Ste-Foy, PQ, Canada |
|
|
15:10
P20 |
PAGET'S OSTEOSARCOMA IN SCOTLAND |
|
S W Hamilton[1], E MacDuff[2],
D E Boddie[1], T R Scotland[1], R Reid[2]
[1]Department of Orthopaedics, Woodend Hospital,
Aberdeen; [2]Scottish Bone Tumour Registry, Western
General Hospital, Glasgow |
|
|
15:15
P21 |
ULTRASTRUCTURAL AND IMMUNOCYTOCHEMICAL CHARACTERISATION
OF INCLUSIONS IN PAGET'S DISEASE AND RELATED DISORDERS |
|
M H Helfrich[1], D I Scott[1],
S Yuen[1], J Greenhorn[1], J C Crockett[1],
L Hocking[1], S H Ralston[2], M J Rogers[1]
[1]University of Aberdeen, Aberdeen, UK; [2]University
of Edinburgh, Edinburgh, UK |
|
|
15:20
P22 |
UP-REGULATION OF THE INTERFERON SIGNALING
PATHWAYS IN MONOCYTES FROM PATIENTS WITH PAGET'S DISEASE OF
BONE |
|
Z B Nagy, P Gergely Jr, J Donáth, G
Poór
National Institute of Rheumatology and Physiotherapy, Budapest,
Hungary |
|
|
15:25 |
Break |
|
|
Update on treatments in Paget’s
Disease |
Chairs: Michael Davie
(Oswestry, UK) & Caje Moniz (London,
UK) |
|
|
15:30 |
Zoledronic acid 5 mg IV in the treatment of
Paget’s Disease of bone |
|
David
Hosking (Nottingham, UK) |
|
|
16:00 |
Tea and close |
|
|
17:00 |
Keynote Lecture |
Chairs: Paul Miller
(Oakwood, USA) & David
Hosking (Nottingham, UK) |
|
|
|
The Paget Family across the generations
Sir Julian Paget
|
|
|
17:30 |
Close |
|
|
19:00 |
Dinner |
|
|
|
|
Saturday
14 July |
PATIENTS’ DAY |
See also Advances in the Molecular
Pharmacology and Therapeutics of Bone Disease,
10-12 July
|
|
|
|
